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Left ventricular hypertrophy is an adopted response to physiological and pathological stress, while 
hypertrophic cardiomyopathy (HCM) is defined by the presence of increased left ventricular wall 
thickness that is not solely explained by abnormal loading conditions. Determination of the etiology, 
pathophysiology and disease severity is important for the management of patients with HCM.1-4
According to latest European Cardiology Society Guidelines for HCM2 , etiology in adults are 60% an 
autosomal dominant trait caused by mutations in cardiac sarcomere protein genes, 5-10% caused by 
other genetic disorders including inherited metabolic and neuromuscular diseases, chromosome ab-
normalities and genetic syndromes, malformation syndromes,  non-genetic disorders that mimic ge-
netic forms of the disease like amyloidosis and infiltrative diseases. In about 25-30% of HCM etiology 
is still unknown.
In adults, HCM is defined by a wall thickness ≥15 mm in one or more LV myocardial segments as 
measured by any imaging technique. Transthoracic 2D and tissue doppler echocardiography pres-
ents tool for morphologic and hemodynamic evaluation (with additional strain analysis, contrast 
and transesophageal echocardiography), and cardiac MRI for assessment of cardiac morphology and 
myocardial tissue characteristics. Routine laboratory tests and specific testing aids the detection of 
HCM etiology. The majority of HCM cases are inherited autosomal dominant genetic trait with a 50% 
risk of transmission to offspring. Some cases are explained by de novo mutations, sporadic cases can 
arise because of incomplete penetrance in a parent and by autosomal recessive inheritance. Regular 
genetic analysis should include the most commonly implicated sarcomere protein genes, and pedi-
gree analysis should be provided. Annual incidence of cardiovascular death is 1–2% caused by sudden 
cardiac death, heart failure or thromboembolism.
HCM etiology detection is necessary because of treatment possibilities (like Anderson-Fabry disease 
or ATTR amyloidosis), detection of secondary causes of disease, the need for family screening and dif-
ferentiating pathogenic from non-pathogenic mutations. Routine clinical practice is challenging, left 
ventricular hypertrophy and HCM can be presented in different forms and different stages. 
